Q32 Bio Inc. (QTTB) corrects director stock option grant to 10,826 options
Rhea-AI Filing Summary
Q32 Bio Inc. director Arthur Tzianabos reported a corrected grant of 10,826 stock options to acquire Common Stock, awarded on June 12, 2026 at an exercise price of $12.64 per share and expiring on June 11, 2036. The options vest and become exercisable in full on the earlier of June 12, 2027 or the company’s next annual meeting of stockholders, subject to his continued service. This amendment updates a Form 4 filed on June 16, 2026 solely to correct the number of options awarded.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
TZIANABOS ARTHUR
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1, F2 | 10,826 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 10,826 shares (Direct)
Footnotes (2)
- F1. This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
- F2. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Key Figures
Options Granted: 10,826 options
Exercise Price: $12.64 per share
Expiration Date: June 11, 2036
+2 more
5 metrics
Options Granted
10,826 options
Stock Option (Right to Buy) granted to director on June 12, 2026
Exercise Price
$12.64 per share
Conversion or exercise price of the stock option award
Expiration Date
June 11, 2036
Option expiration for the 10,826 stock options granted
Vesting Trigger Date
June 12, 2027
Earlier of this date or next annual meeting, subject to continued service
Post-Transaction Options Held
10,826 options
Total options from this award following the reported grant
Key Terms
Stock Option (Right to Buy), Common Stock, annual meeting of stockholders, vest and become exercisable
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
annual meeting of stockholders financial
"the date of the Issuer's next annual meeting of stockholders"
vest and become exercisable financial
"shares underlying this option shall vest and become exercisable in full"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Q32 Bio Inc. (QTTB) report in this amended Form 4?
Q32 Bio Inc. reported a stock option grant to director Arthur Tzianabos. He received 10,826 options to acquire Common Stock, with specific vesting terms and an exercise price detailed as part of his director compensation.
How many stock options were granted to Arthur Tzianabos in QTTB’s latest filing?
Arthur Tzianabos was granted 10,826 stock options. The amended filing states this figure corrects the number of options originally reported, and reflects his total option holdings from this award following the transaction.
What is the exercise price and expiration date of the QTTB options granted to Arthur Tzianabos?
The options granted to Arthur Tzianabos have an exercise price of $12.64 per share and an expiration date of June 11, 2036, defining the price and time window during which they may be exercised once vested.
What are the vesting terms of the 10,826 QTTB stock options granted to Arthur Tzianabos?
The 10,826 options vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, provided Arthur Tzianabos continues his service through the applicable vesting date.
Why did Q32 Bio Inc. (QTTB) file an amended Form 4 for Arthur Tzianabos?
The company filed this amendment solely to correct the number of options reported as awarded on June 12, 2026. The earlier Form 4 filed on June 16, 2026 contained an incorrect option count for this grant.
Was the QTTB option grant to Arthur Tzianabos reported under a Rule 10b5-1 trading plan?
The Rule 10b5-1 checkbox in the filing is not marked, so this grant is not identified as made pursuant to a Rule 10b5-1 trading plan, and instead appears as a standard director equity award.